Catalog No.
Product Name
Application
Product Information
Citations
-
P2Y12 Receptor Inhibitor
(±)-Clopidogrel bisulfate is an inhibitor of the platelet P2Y12 receptor and serves as an adenosine diphosphate (ADP) receptor antagonist. By blocking ADP binding to its receptors on platelet membranes, (±)-Clopidogrel bisulfate effectively attenuates ADP-mediated glycoprotein GPIIb/IIIa complex activation. This compound is utilized in research investigating its role in reducing vascular inflammation and mitigating the progression of angiotensin II-induced abdominal aortic aneurysms, as well as exploring its anti-inflammatory properties. -
P2Y Receptor Inhibitor
PSB-16133 sodium is a potent P2Y receptor inhibitor that selectively targets various P2Y receptor subtypes. This compound is valuable for studying purinergic signaling pathways and understanding their roles in physiological and pathological processes. PSB-16133 sodium can be utilized in research applications focusing on inflammation, cardiovascular disorders, and neuronal signaling. -
P2Y Receptor Antagonist
Selatogrel is a reversible and selective P2Y12 receptor antagonist, effectively inhibiting platelet aggregation with an IC50 of 8 nM. This compound demonstrates significant antithrombotic activity, making it a valuable tool for research in cardiovascular disease, particularly in studies focused on thrombus formation and prevention. Selatogrel's specific mechanism of action allows for targeted investigations into the role of platelet inhibition in various pathological conditions. -
P2Y1/P2Y12 Antagonist
P2Y1/P2Y12 antagonist-1 is a dual inhibitor targeting the P2Y1 and P2Y12 receptors, providing significant antiplatelet activity. This compound effectively inhibits ADP-induced platelet aggregation in rabbit plasma, demonstrating an IC50 value of 4.23 μM. Additionally, P2Y1/P2Y12 antagonist-1 shows potent inhibitory effects in a rat thrombosis model, making it a valuable tool for research on platelet function and related cardiovascular conditions. -
P2Y₁₂ Receptor Inhibitor
R-138727 is a potent and selective irreversible antagonist of the P2Y12 receptor, functioning as a key inhibitor with an IC50 of 2.5 μM. This compound covalently binds to the P2Y12 receptor present on platelet surfaces, effectively blocking adenosine diphosphate-mediated platelet activation and aggregation. R-138727 is valuable for research applications targeting stroke, cerebral infarction, and associated neurological deficits. -
P2Y1 Receptor Antagonist
MRS2279 diammonium is a selective antagonist of the P2Y1 receptor, exhibiting high affinity with a Ki value of 2.5 nM and an IC50 of 51.6 nM. This compound competitively inhibits ADP-induced platelet aggregation, demonstrated by a pKb value of 8.05. MRS2279 diammonium is valuable for studies investigating platelet function and thrombotic diseases. -
P2Y1 Receptor Antagonist
MRS2179 tetrasodium is a competitive antagonist of the P2Y1 receptor, demonstrating a Kb value of 102 nM and a pA2 of 6.99 for the turkey P2Y1 receptor. This compound exhibits selectivity for P2Y1 over other purinergic receptors, including P2X1 (IC50 = 1.15 µM) and P2X3 (IC50 = 12.9 µM). MRS2179 tetrasodium is particularly useful in studies of platelet aggregation and various signaling pathways involving purinergic receptors. -
P2Y2R Agonist
MRS2768 tetrasodium salt is a selective agonist for the P2Y2 receptor. This compound demonstrates protective effects on cardiomyocytes against ischemic damage both in vivo and in vitro, making it a valuable tool for research into cardiovascular diseases. Its ability to activate P2Y2 receptors can aid in studying various biological processes related to cell survival and tissue protection. -
P2Y12 Receptor Antagonist
Regrelor disodium is a reversible antagonist of the P2Y12 receptor, functioning as a competitive inhibitor of ADP. This compound demonstrates significant inhibitory effects on platelet activation and aggregation, making it valuable in studies focusing on thrombus formation and cardiovascular disease. Additionally, Regrelor disodium has been shown to inhibit cell proliferation, thereby finding applications in inflammation-related research. -
P2Y12 Antagonist
2-Methylthio-AMP diTEA is a selective and direct antagonist of the P2Y12 receptor. This compound effectively inhibits ADP-dependent platelet aggregation, making it a valuable tool for studying platelet function and thrombosis-related pathways in cardiovascular research. Its specificity for the P2Y12 receptor allows for detailed exploration of purinergic signaling and potential therapeutic applications in platelet-mediated disorders. -
P2Y1 Antagonist
Adenosine 2',5'-diphosphate sodium is a competitive antagonist of the P2Y1 receptor. It demonstrates non-selective antagonistic activity at both recombinant and human platelet P2X1 receptors. This compound is useful in research applications focusing on purinergic signaling pathways and the modulation of platelet activation. -
P2Y11 Agonist
NF546 is a selective non-nucleotide agonist of the P2Y11 receptor, exhibiting a pEC50 of 6.27. This compound effectively stimulates the release of interleukin-8 from human monocyte-derived dendritic cells, making it valuable for research focused on immune response modulation and inflammation pathways. Its targeted action on P2Y11 highlights its potential in studying purinergic signaling and associated biological functions. -
P2X1/ P2Y1 Receptor Antagonist
Blue FPG-A trisodium is a selective antagonist of the P2X1 and P2Y1 receptors, exhibiting IC50 values of 35.5 μM and 2.6 μM, respectively. This compound serves as a valuable tool for investigating purinergic signaling pathways and their implications in various physiological and pathological processes. Its structural relationship to Reactive Blue 2 (RB2) further supports its utility in biochemical assays and research applications focused on receptor interactions and cellular signaling mechanisms. -
P2Y2/P2Y4 Agonist
Uridine-5'-O-(3-thiotriphosphate) trisodium is a stable analogue of UTP that acts as a potent agonist of the P2Y2 and P2Y4 receptors. Its increased metabolic stability enhances its effectiveness in various biological studies. This compound is valuable for research applications involving purinergic signaling and receptor physiology. -
P2Y12 Receptor Antagonist
SAR216471 hydrochloride is a potent P2Y12 receptor antagonist that exhibits significant antiplatelet and antithrombotic activities in vivo. By inhibiting P2Y12 receptor signaling, it offers valuable insights into the mechanisms of platelet activation and thrombosis. This compound is suitable for research applications studying cardiovascular diseases and thromboembolic disorders. -
P2Y1 Antagonist
BMS-884775 is a potent and selective antagonist of the P2Y1 receptor, exhibiting an IC50 of 0.1 nM for the human target. This compound demonstrates significant antiplatelet activity, effectively preventing arterial thrombosis while minimizing bleeding risk and duration compared to other antiplatelet agents. BMS-884775 is a valuable tool for research in the fields of cardiovascular disease and arterial thrombosis management, offering insights into therapeutic strategies for related health conditions. -
P2Y12 Receptor Ligand
PSB-22219 is a highly selective non-nucleotidic ligand for the P2Y12 receptor, with a binding affinity of KD=4.57 nM. This compound demonstrates significant promise in the study of P2Y12 receptor-mediated neuroinflammation, making it a valuable tool for research applications in neurobiology and related fields. Its specificity and efficacy facilitate investigations into the role of P2Y12 in various pathological conditions. -
P2Y6R Agonist
UTPU trisodium is a selective agonist of the P2Y6 receptor, exhibiting an EC50 of 0.4 μM. This compound effectively activates intracellular calcium signaling pathways mediated by P2Y6, making it a valuable tool for studying inflammatory processes. UTPU trisodium is suitable for research applications focused on inflammation and related signaling mechanisms. -
P2Y1 Receptor Antagonist
MRS-2179 is a selective competitive antagonist of the P2Y1 receptor, exhibiting a binding affinity with a KB value of 0.177 μM. This compound plays a crucial role in molecular research focused on purinergic signaling, enabling the investigation of cellular responses mediated by ATP. MRS-2179 is valuable for studying its implications in various physiological and pathological processes, including cardiovascular function and platelet aggregation. -
P2Y Receptor Agonist
MRS2957 is a selective agonist of the P2Y6 receptor, which plays a crucial role in activating AMP-activated protein kinase (AMPK) in pancreatic β-cells. This activation promotes insulin secretion while reducing apoptosis, highlighting its potential as a therapeutic target for type 2 diabetes. MRS2957 may provide valuable insights in research focused on diabetes treatment and pancreatic function. -
P2Y₁₄ Receptor Agonist
UDP-Galactose is a glycosyl donor molecule and a natural agonist of the P2Y14 receptor, which is coupled to Gi proteins in immune responses. It exhibits significant biological activity with an IC50 value of 0.67 μM for human P2Y14 receptor activation. This reagent is valuable for research applications investigating cell signaling pathways and nucleotide sugar metabolism. -
P2Y12 Receptor Antagonist
AR-C66096 is a selective antagonist of the Gi-coupled P2Y12 receptor, known for its potent ability to inhibit ADP-induced platelet aggregation. This compound effectively reduces thrombus stability under physiological flow conditions, making it a valuable tool for antithrombotic research. Its application in studying platelet function and thrombus formation can provide insights into cardiovascular diseases and therapeutic interventions. -
P2Y11 Receptor Inhibitor
NF340 is a selective inhibitor of the P2Y11 receptor, achieving a pIC50 of 7.3-7.7 in human cells. It effectively blocks nociceptive signaling and alleviates the upregulation of P2Y11 receptors in the spinal dorsal horn following spinal cord injury. NF340 further inhibits the NFκB signaling pathway induced by IL-1β, leading to a reduction in pro-inflammatory cytokine expression and a decrease in intracellular ROS levels. Additionally, it suppresses ATP-induced calcium influx and cell migration in human hepatocellular carcinoma cells. NF340 is relevant for research into neuropathic pain, myocardial ischemia/reperfusion injury, inflammatory pain, rheumatoid arthritis, and hepatocellular carcinoma. -
P2Y4 Receptor Agonist
mrs 4062 TEA is a selective agonist of the P2Y4 receptor, exhibiting a potent EC50 of 23 nM. This compound also demonstrates moderate activity against the P2Y2 and P2Y6 receptors, with EC50 values of 640 nM and 740 nM, respectively. mrs 4062 TEA is valuable in research focused on purinergic signaling and its implications in various physiological processes and disease states. -
P2Y14R Antagonist
MRS4833 is a potent, orally active antagonist of the P2Y14 receptor, exhibiting competitive inhibition with IC50 values of 5.92 nM for human and 4.8 nM for mouse P2Y14R. This compound effectively reduces airway eosinophilia in protease-mediated asthma models and has demonstrated the ability to reverse chronic neuropathic pain in mouse models of chronic constriction injury. MRS4833 is valuable for research investigating P2Y14R-related pathways in asthma and pain management. -
P2Y12 Antagonist
2-Methylthio-AMP sodium is a selective antagonist of the P2Y12 receptor, known for its inhibitory effects on ADP-dependent platelet aggregation. This compound is utilized in research focused on thrombus formation and cardiovascular diseases, providing insights into platelet function and potential therapeutic interventions for thrombotic disorders. Its specificity for P2Y12 makes it a valuable tool in understanding the mechanisms of platelet activation and inhibition. -
P2Y1 Antagonist
P2Y1 Antagonist 4 is a selective antagonist of the P2Y1 receptor, demonstrating significant inhibition of receptor-mediated cytosolic calcium increase (IC50 = 1.95 μM) and platelet aggregation (IC50 = 3.24 μM) induced by ADP in rabbit washed platelets. This compound effectively penetrates the blood-brain barrier and has been shown to upregulate nuclear Nrf2 protein levels in H2O2-treated HT22 cells. Additionally, P2Y1 Antagonist 4 reduces myocardial infarct size in a mouse model of acute myocardial infarction, making it a valuable tool for research in ischemic stroke and myocardial infarction. -
P2Y receptor Agonist
2-MeSADP is a potent agonist for P2Y receptors, exhibiting an EC50 of 5 nM for human P2Y12 and EC50 values of 19 nM and 13 nM for human P2Y13, with an EC50 of 6.2 nM for mouse P2Y13. This compound preferentially activates P2Y12 over P2Y13 and induces increases in intracellular calcium levels, Gi-mediated cAMP inhibition, and adenylate cyclase inhibition, facilitating downstream signaling pathways. 2-MeSADP is suitable for investigations into various biological processes, including research related to glaucoma. -
P2Y14 Receptor Antagonist
MRS4608 is a selective antagonist of the P2Y14 receptor, exhibiting IC50 values of 20 nM for the human P2Y14 receptor and 21.4 nM for the mouse counterpart. This compound demonstrates anti-inflammatory properties and has been shown to reduce eosinophil infiltration. MRS4608 is valuable for research in inflammation and immunology, with specific applications in studies related to asthma. -
P2Y Receptor Agonist
2-Thio-UTP tetrasodium is a potent agonist of the P2Y2, P2Y4, and P2Y6 receptors. It plays a crucial role in cell signaling pathways involved in cancer research, facilitating the study of tumor microenvironments and cellular responses. This compound is valuable for investigating therapeutic targets related to purinergic signaling in various cancers. -
P2Y12 Antagonist
SAR216471 is a selective P2Y12 receptor antagonist that reversibly inhibits the binding of 2MeSADP to P2Y12 receptors, demonstrating an IC50 of 17 nM in vitro. This compound effectively inhibits platelet aggregation and displays anti-thrombotic activity in rat models. SAR216471 is pertinent for investigations into thrombosis and related cardiovascular research applications. -
P2Y Receptor Antagonist
MRS4865 is a selective antagonist of the P2Y14 receptor, designed to inhibit its biological activity. This compound demonstrates significant potential in mitigating neuropathic pain through its unique dual mechanism, which combines antagonist properties with UDP-glucose agonist functionality. MRS4865 is suitable for research applications exploring pain pathways and P2Y receptor signaling, making it a valuable tool for studying neuropharmacology and therapeutic interventions for pain management. -
P2Y14-R Antagonist
PPTN mesylate is a selective antagonist of the P2Y14 receptor, demonstrating a high affinity with a KB value of 434 pM. It exhibits no agonistic or antagonistic effects on other P2Y receptor subtypes, including P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13. This compound has potential applications in research focused on anti-inflammatory and immune modulation mechanisms. -
P2Y12 Receptor Antagonist
Becondogrel is a P2Y12 receptor antagonist that functions as a potent metabolite of Clopidogrel. It irreversibly inhibits the P2Y12 receptor, leading to the inhibition of platelet aggregation and thrombosis. This compound is valuable for research in cardiovascular diseases and thrombotic disorders, providing insights into antiplatelet therapies and the mechanisms underlying platelet function. -
P2Y Receptor Antagonist
MRS2567 is a selective antagonist of P2Y receptors, effectively inhibiting the contraction of mouse mesenteric arteries. This compound disrupts sustained contractions induced by UTP and UDP, and modulates the Na+, K+, 2Cl- co-transport-dependent signaling pathway, thereby influencing the myogenic tone in these blood vessels. MRS2567 is valuable for research into vascular function and receptor signaling mechanisms. -
P2Y1 Receptor Antagonist
MRS2279 is a selective antagonist of the P2Y1 receptor, demonstrated by a Ki value of 2.5 nM and an IC50 of 51.6 nM. This compound effectively inhibits ADP-induced platelet aggregation in a competitive manner, with an apparent affinity of pKB = 8.05. MRS2279 is valuable for research applications involving platelet function and signaling pathways related to purinergic receptors. -
P2YR Activator
Sp-UTP-α-S (Uridine 5'-O-1-thiotri-phosphate) functions as an activator of P2Y2 and P2Y4 receptors. This compound is particularly useful in cancer research, where it can help elucidate the roles of purinergic signaling in tumor biology. By activating these receptors, Sp-UTP-α-S may contribute to studies related to cell proliferation, migration, and signaling pathways associated with cancer progression. -
P2Y2 Receptor Agonist
PSB-1114 tetrasodium is a potent agonist of the P2Y2 receptor, exhibiting an EC50 of 134 nM and demonstrating significant enzymatic stability. This compound is highly selective, showing over 50-fold selectivity against the P2Y4 and P2Y6 receptors, with EC50 values of 9.3 μM and 7.0 μM, respectively. PSB-1114 tetrasodium is valuable for research applications focusing on P2Y2 receptor-mediated signaling pathways and related physiological processes. -
P2Y12 Receptor Antagonist
MRS2395 is a potent antagonist of the P2Y12 receptor, a key regulator of platelet activity. It effectively inhibits ADP-induced platelet activation with a half-maximal inhibitory concentration (Ki) of 3.6 μM and suppresses cAMP production in rat platelets in the presence of PGE1 with an IC50 of 7 µM. Additionally, MRS2395 promotes the release of dense granules from platelets in response to TRAP-6, making it a valuable tool for research into platelet function and thrombotic disorders. -
P2Y6 Receptor Agonist
5-OMe-UDP, a potent P2Y6 receptor agonist with an EC50 of 0.08 μM, activates the P2Y6 receptor by binding and initiating intracellular signaling cascades. This activation results in increased intracellular calcium ion concentration, influencing various cellular functions. The presence of methoxy groups in 5-OMe-UDP enhances its selectivity and activity, making it a valuable tool for investigating pathologies associated with P2Y6 receptor function, including diabetes, inflammatory bowel disease, and Alzheimer's disease. -
P2Y2/P2Y4 Agonist
Uridine-5'-O-(3-thiotriphosphate) (UTPγS) is a stable analogue of Uridine triphosphate (UTP) that acts as a potent agonist for the P2Y2 and P2Y4 receptors. It demonstrates significant biological activity by stimulating inositol phosphate formation in human 1321N1 astrocytoma cells that express the phospholipase C-coupled human P2U-purinoceptor, with an EC50 value of 240 nM. This compound is valuable for research applications focused on purinergic signaling and receptor pharmacology. -
P2Y1R Antagonist
Desmodilactone is an allosteric antagonist of the P2Y1 receptor. It exhibits significant potential in modulating platelet activation and aggregation, thereby contributing to research on thrombosis and related cardiovascular conditions. This compound can be utilized in studies aimed at understanding P2Y1 signaling pathways and developing targeted therapies for thrombotic diseases. -
P2Y12 Antagonist
ACT-281959 is an orally bioavailable prodrug of Selatogrel, functioning as a P2Y12 receptor antagonist. This reagent effectively inhibits platelet aggregation, making it a valuable tool for investigating cardiovascular diseases and related pathophysiological mechanisms. Its utility in research can aid in the development of therapeutic strategies targeting thrombotic disorders. -
P2Y1 Antagonist
P2Y1 antagonist 1 is a highly effective antagonist of the P2Y1 receptor, exhibiting IC50 values of 1.1 nM in the FLIPR assay and 0.24 μM in the hPA assay. This compound is crucial for advancing antiplatelet research, providing insights into the modulation of platelet activation and implications for cardiovascular therapeutics. Its potent inhibitory action makes it a valuable tool for studying P2Y1-related biological pathways. -
P2Y1 Antagonist
Adenosine 3'-phosphate 5'-phosphosulfate is a selective antagonist of the P2Y1 receptor, effectively inhibiting ADP-induced platelet aggregation without affecting P2Y2, P2Y4, or P2Y6 receptors. This compound disrupts the ability of ADP to induce shape change and elevate intracellular Ca2+ levels in platelets while not influencing ADP's inhibition of adenylate cyclase. In addition to its antagonistic properties, Adenosine 3'-phosphate 5'-phosphosulfate serves as a co-substrate for glycan sulfonation, and can be utilized in Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays for sulfonate group transfer. -
P2Y2/P2Y4 Activator
Ap4C tetrasodium is an activator of P2Y2 and P2Y4 receptors, functioning as a signaling molecule through its interaction with these purinergic receptors. It induces platelet aggregation and mediates various cellular responses, making it a key reagent in the study of inflammation and blood coagulation pathways. This compound is valuable for research applications focusing on the pharmacology of platelet function and related vascular processes. -
P2Y Receptor Antagonist
P2Y12 antagonist 1 is a P2Y12 receptor antagonist, exhibiting a Ki of 3.13 μM. This compound effectively inhibits platelet aggregation, making it a promising candidate for antithrombotic applications in cardiovascular research. Its role in modulating P2Y12 receptor activity highlights its potential for investigating platelet function and thrombus formation. -
P2Y1/13 Receptor Antagonist
MRS2603 is a pyridoxal derivative that acts as a potent antagonist of the P2Y1 and P2Y13 receptors. This compound exhibits significant biological activity by inhibiting the signaling pathways mediated by these purinergic receptors. MRS2603 is valuable for research applications involving the modulation of purinergic signaling and the study of various physiological processes and disease mechanisms associated with P2Y receptor activity. -
P2Y1 Receptor Antagonist
MRS2496 is a selective antagonist of the P2Y1 receptor, exhibiting an IC50 value of 1.5 μM. This compound effectively demonstrates antiplatelet aggregation activity, making it a valuable tool in the study of antiplatelet mechanisms. MRS2496 is applicable in research focused on blood-related diseases, offering insights into therapeutic strategies for conditions involving platelet function. -
P2Y14 Receptor Agonist
UDP-GlcNAc serves as a full agonist of the P2Y14 receptor, a key mediator in various cellular signaling pathways. It plays a crucial role in inhibiting adenosine 3',5'-monophosphate (cAMP) formation, providing insight into metabolic processes and receptor signaling. This compound is particularly valuable in research related to bacterial infections and the study of peptidoglycan biosynthesis.
